

News Release

Biofrontera AG
("Biofrontera" or the "Company")

Issue of equity and total voting rights

Leverkusen, 10 December 2015 – Biofrontera AG (AIM/FSE: B8F), the biopharmaceutical company focusing on sun induced skin cancer, announces that it has issued and allotted 1,916,588 Ordinary Shares of no par value each ("Ordinary Shares") pursuant to the Open Offer and Private Placement announced on 27 October 2015.

Application has been made for the 1,916,588 new Ordinary Shares to be admitted to trading on AIM and it is expected that admission will take place on or about 8:00 a.m. on 11 December 2015 ("Admission"). The 1,916,588 new Ordinary Shares will also be registered and admitted to trading on the Frankfurt and Düsseldorf Stock Markets.

In accordance with the Disclosure and Transparency Rules (DTR 5.6.1R) the Company hereby notifies the market that immediately following registration and Admission its issued share capital will consist of 25,490,430 Ordinary Shares. The Company does not hold any shares in treasury. Shareholders may use these figures as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Ends

Enquiries, please contact:

Biofrontera AG Thomas Schaffer, Chief Financial Officer	+49 (0) 214 87 63 2 0 press@biofrontera.com www.biofrontera.com
IR Germany: Brainwell Asset Solutions Jürgen Benker	+49 (0) 152 08931514
Nomad and Broker: Shore Capital Bidhi Bhoma / Toby Gibbs	+44(0) 20 7408 4090
IR UK: Seton Services Toni Vallen	+44(0) 20 7729 0805
Financial PR: Gable Communications John Bick / Justine James	+44(0) 20 7193 7463 +44 (0)7872 061007

Background:

Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is **Ameluz[®]**, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz[®] to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

News Release

The company also markets the Belixos[®] dermatological range of cosmetics. Belixos[®] products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos[®] Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.